KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal

Source: 
Fierce Biotech
snippet: 

KRAS and its hope against cancer was one of the biggest talking points in 2019, and it seems this hype is not dying down in 2020.

This morning, Merck & Co. said it was willing to put as much as $2.5 billion on the table (though very heavily backloaded) to gain access to small-molecule inhibitors against several drug targets, including the KRAS oncogene, from Taiho and Astex.